484 related articles for article (PubMed ID: 7812959)
1. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
[TBL] [Abstract][Full Text] [Related]
2. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
[TBL] [Abstract][Full Text] [Related]
3. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
[TBL] [Abstract][Full Text] [Related]
4. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
[TBL] [Abstract][Full Text] [Related]
6. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
[TBL] [Abstract][Full Text] [Related]
7. An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer.
Zhang QX; Borg A; Fuqua SA
Cancer Res; 1993 Dec; 53(24):5882-4. PubMed ID: 8261397
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line.
Madsen MW; Reiter BE; Lykkesfeldt AE
Mol Cell Endocrinol; 1995 Apr; 109(2):197-207. PubMed ID: 7664983
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
[TBL] [Abstract][Full Text] [Related]
10. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer.
Murphy LC; Hilsenbeck SG; Dotzlaw H; Fuqua SA
Clin Cancer Res; 1995 Feb; 1(2):155-9. PubMed ID: 9815968
[TBL] [Abstract][Full Text] [Related]
11. A novel estrogen receptor variant mRNA lacking exons 4 to 6 in breast carcinoma.
Chan CM; Dowsett M
J Steroid Biochem Mol Biol; 1997 Aug; 62(5-6):419-30. PubMed ID: 9449245
[TBL] [Abstract][Full Text] [Related]
12. Function of the exon 7 deletion variant estrogen receptor alpha protein in an estradiol-resistant, tamoxifen-sensitive human endometrial adenocarcinoma grown in nude mice.
Horvath G; Leser G; Helou K; Henriksson M
Gynecol Oncol; 2002 Feb; 84(2):271-9. PubMed ID: 11812086
[TBL] [Abstract][Full Text] [Related]
13. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors.
Zhang QX; Hilsenbeck SG; Fuqua SA; Borg A
J Steroid Biochem Mol Biol; 1996 Nov; 59(3-4):251-60. PubMed ID: 9010317
[TBL] [Abstract][Full Text] [Related]
14. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
15. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
[TBL] [Abstract][Full Text] [Related]
16. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
17. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
McClelland RA; Manning DL; Gee JM; Anderson E; Clarke R; Howell A; Dowsett M; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 1996; 41(1):31-41. PubMed ID: 8932874
[TBL] [Abstract][Full Text] [Related]
18. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
19. Variant human breast tumor estrogen receptor with constitutive transcriptional activity.
Fuqua SA; Fitzgerald SD; Chamness GC; Tandon AK; McDonnell DP; Nawaz Z; O'Malley BW; McGuire WL
Cancer Res; 1991 Jan; 51(1):105-9. PubMed ID: 1988075
[TBL] [Abstract][Full Text] [Related]
20. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]